Mid-Michigan's Bigger Dealer With Better Deals
NSI-189 NOOTROPIC ≥98% CAS 1270138-40-3
NSI-189 Dosage: Neuralstem, Inc. is currently running clinical trials for its use in major depressive disorder, in addition to treating cognitive impairments, and brain degeneration. NSI-189 stimulates neurogenesis of the human hippocampus. NSI-189 dosage was 40 mg-80 mg daily for 12 weeks.NSi-189 powder
NSI-189 increases sociability interactions while enhancing confidence and improved life decisions that lead to elevated sexual enjoyment and quality of life.
NSI-189 stimulates neurogenesis of the human hippocampus.
Modern antidepressants focus on the monoamine neurotransmitter system. However, 66% of people treated for major depression disorder achieve clinically significant improvements.
Current antidepressants have long term side effects with negative consequences. Neuralstem Inc proposes that NSI-189 uses different pathways.
Ability to control emotions that continue after cessation
Being fluent in speaking and writing.
Improved memory energy
Sharpness of vision
Logical and emotional difficulties resolve
Increased sexual enjoyment and quality of life.
Sociability and interactions are maintained with ease
Confidence while enhancing confidence and improved life decisions.
Reports indicate that suicidal tendencies disappear and personal relationships improve with a broad spectrum of reporting.